All results
1 results for impact
-
TN-31 JAKPOT T1D
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and…
- Ages
- 12 Years - 35 Years
- Sexes
- All